If you are wondering whether Novavax (Nasdaq: NVAX) is priced attractively or already reflects its story, you are not alone. The stock last closed at US$9.75, with returns of 21.7% over 7 days, 40.5% ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M ...

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.

Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of ...

Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M. Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.